+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome (SBS) - Global Market Trajectory & Analytics

  • ID: 5309856
  • Report
  • April 2021
  • Region: Global
  • 132 pages
  • Global Industry Analysts, Inc
Global Short Bowel Syndrome (SBS) Market to Reach $3.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Short Bowel Syndrome (SBS) estimated at US$665.4 Million in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 27.6% over the analysis period 2020-2027. GLP-2, one of the segments analyzed in the report, is projected to record a 29% CAGR and reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Growth Hormone segment is readjusted to a revised 26.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $199.7 Million, While China is Forecast to Grow at 26.8% CAGR

The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$199.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$627.8 Million by the year 2027 trailing a CAGR of 26.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 25% and 23.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19.2% CAGR.

Glutamine Segment to Record 23.6% CAGR

In the global Glutamine segment, USA, Canada, Japan, China and Europe will drive the 23.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$19.7 Million in the year 2020 will reach a projected size of US$86.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433 Million by the year 2027.

Select Competitors (Total 42 Featured):
  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for GLP-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Glutamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 16: USA Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • CANADA
  • Table 19: Canada Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: Canada Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: Canada 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 22: Japan Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: Japan Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: Japan 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • CHINA
  • Table 25: China Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: China Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: China 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 28: Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 29: Europe Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 31: Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 34: France Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: France Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: France 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 37: Germany Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: Germany Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: Germany 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • ITALY
  • Table 40: Italy Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Italy Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Italy 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 43: UK Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: UK Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: UK 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 46: Rest of Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 49: Asia-Pacific Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Asia-Pacific 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 52: Rest of World Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: Rest of World 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll